EAST NORRITON, Pa., Oct. 12 /PRNewswire-FirstCall/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that it will host an Analyst and Investor Meeting on Wednesday, October 27, 2010 in New York, New York. Tengion's management team will provide an update on the Company's product development portfolio and upcoming corporate milestones, and will expand on recently presented data from the Neo-Kidney Augment™ program.
The live webcast of the event will be available under the Investors section of the Company's website at www.tengion.com and will begin at 1:00 pm ET and will end at approximately 3:00 pm ET. To participate in the webcast, please pre-register at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=218965&eventID=3420638.
An archive of the event will be available on the Company's website.
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. Tengion commenced a Phase I clinical trial in the first half of 2010 for its lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder and is in preclinical development of its Neo-Kidney Augment™. Tengion has worldwide rights to its product candidates.
|SOURCE Tengion, Inc.|
Copyright©2010 PR Newswire.
All rights reserved